Long‐Term Risk of Type 2 Diabetes Associated With Topical Corticosteroid Use: A Nationwide Population‐Based Cohort Study in Korea
Advances in Pharmacological and Pharmaceutical Sciences · 2026-01 · 2026 (1)
DOI: 10.1155/adpp/8843438 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Advances in Pharmacological and Pharmaceutical Sciences, online erschienen am 28.05.2026. Verfasst von Seungwoo Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: FELZ Inc., Goyang-si, Gyeonggi-do, South Korea. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science, ICT and Future Planning.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Steroid‐induced diabetes mellitus (SIDM) is a well‐known side effect of corticosteroid agents. While diabetes induced by systemic corticosteroids has been extensively studied for over 60 years, evidence regarding the association between topical corticosteroids and Type 2 diabetes remains limited. This study aimed to investigate the relationship between topical corticosteroid use and the risk of Type 2 diabetes. A nationwide, population‐based cohort study was conducted using data from the Korea National Health Insurance Service National Sample Cohort Database (NHIS‐NSC2). A total of 186,057 adults without prior Type 2 diabetes were included in the cohort for follow‐up. Among these, 14,944 adults who had been treated with topical corticosteroids and 171,113 adults with no history of topical corticosteroid use were included and followed prospectively for approximately 9 years. The primary outcome was the incidence of Type 2 diabetes following topical corticosteroid use, with additional analyses by frequency and potency of corticosteroid use. Kaplan–Meier curves and Cox proportional hazard models were used to estimate hazard ratios (HR) for Type 2 diabetes. The use of topical corticosteroids was significantly associated with an increased risk of Type 2 diabetes (adjusted HR [aHR] 1.13, 95% CI 1.06–1.20). The high‐frequency corticosteroid group demonstrated the highest risk (aHR 1.27, 95% CI 1.09–1.48), while the moderate‐potency corticosteroid group also showed a significant increase in risk (aHR 1.15, 95% CI 1.04–1.27). Notably, the diabetes risk in the moderate‐potency group was comparable to that observed in the systemic corticosteroid group (aHR 1.20, 95% CI 1.14–1.26). In this study, the use of topical corticosteroids was significantly associated with the incidence of Type 2 diabetes. These findings highlight the importance of considering diabetes risk factors when prescribing topical corticosteroids.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- FELZ Inc., Goyang-si, Gyeonggi-do, South Korea.
- International Health Promotion Center, Ewha Womans University Seoul Hospital, Seoul, South Korea.
- Department of Family Medicine, Ewha Womans University Seoul Hospital, Seoul, South Korea.
- Advanced Biomedical Research Institute, Ewha Womans University Seoul Hospital, Seoul, South Korea.
ORCID-Profile: Seungwoo Kim, Ji Hui An, In Sun Ryou, Yongho Jee
Förderung
- Ministry of Science, ICT and Future Planning
Zitieren
APA
Kim, S., An, J. H., Ryou, I. S., & Jee, Y. (2026). Long‐Term Risk of Type 2 Diabetes Associated With Topical Corticosteroid Use: A Nationwide Population‐Based Cohort Study in Korea. Advances in Pharmacological and Pharmaceutical Sciences, 2026(1). https://doi.org/10.1155/adpp/8843438
Vancouver
Kim S, An JH, Ryou IS, Jee Y. Long‐Term Risk of Type 2 Diabetes Associated With Topical Corticosteroid Use: A Nationwide Population‐Based Cohort Study in Korea. Advances in Pharmacological and Pharmaceutical Sciences. 2026;2026(1). doi:10.1155/adpp/8843438
BibTeX
@article{Kim2026,
author = {Kim, Seungwoo and An, Ji Hui and Ryou, In Sun and Jee, Yongho},
title = {Long‐Term Risk of Type 2 Diabetes Associated With Topical Corticosteroid Use: A Nationwide Population‐Based Cohort Study in Korea},
journal = {Advances in Pharmacological and Pharmaceutical Sciences},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/adpp/8843438}
}
EUVIMED